Use of 5&#945;-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.

Rabbani, Sirus; Mattsson, Fredrik; Lagergren, Jesper; Xie, Shaohua

Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.

Rabbani, Sirus; Mattsson, Fredrik; Lagergren, Jesper; Xie, Shaohua.

Afiliação

Rabbani S; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Mattsson F; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lagergren J; Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Xie S; School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.

Acta Oncol ; 62(5): 438-443, 2023 May.

Article em En | MEDLINE | ID: mdl-37216488

Assuntos

Adenocarcinoma; Neoplasias Esofágicas; Neoplasias Gástricas; Masculino; Humanos; Estudos de Coortes; Inibidores de 5-alfa Redutase/uso terapêutico; Neoplasias Gástricas/tratamento farmacológico; Suécia/epidemiologia; Neoplasias Esofágicas/tratamento farmacológico; Adenocarcinoma/patologia; Oxirredutases

Palavras-chave

5-alpha reductase inhibitors; Stomach neoplasms; gonadal steroid hormones; oesophageal neoplasms; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google